TwitterRSSFacebookDirectors Blog
  Disorders A - Z:   A    B   C    D    E    F    G    H    I    J    K    L    M    N    O    P    Q    R    S    T    U    V    W    X    Y    Z

You Are Here: Home  »  Research Funding  »  Offices & Programs  »  Office of Translational Research  » 

Skip secondary menu

Innovation Grants to Nurture Initial Translational Efforts (IGNITE)


Contact for More Information

IGNITE Staff

Amir Tamiz
IGNITE Program Director

Mary Ann Pelleymounter
IGNITE Program Manager

John Sheridan
IGNITE Program Specialist

NINDS launched in December 2014 a new suite of early-stage therapy development funding programs, called The Innovation Grants to Nurture Initial Translational Efforts (IGNITE). IGNITE is meant to serve a feeder program to the later-stage therapy development programs that NINDS launched in July 2014, namely the Cooperate Research to Enable and Advance Translational Enterprises (CREATE) for Biologics and Blueprint Neurotherapeutics (BPN) Programs. 


The IGNITE suite has three funding opportunities:

 1. PAR-15-070: Assay Development and Therapeutic Agent Identification and Characterization to Support Therapeutic Discovery (R21/R33)

This funding opportunity announcement (FOA) encourages research grant applications to develop in vitro and/or ex vivo assays and conduct iterative screening efforts to identify and characterize potential therapeutic agents for neurological disorders. 

Receipt Dates: February 16, June 16, October 16

2. PAR-15-071: Pharmacodynamics and In vivo Efficacy Studies for Small Molecules and Biologics/Biotechnology Products (R21/R33)

This FOA provides funding to conduct pharmacodynamics, pharmacokinetics, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development to treat neurological disorders. Therapeutic agents may include but are not limited to small molecules, biologics or biotechnology-derived products.

Receipt Dates: February 16, June 16, October 16

3.  RFA-NS-16-013: Development and Validation of Model Systems and/or Pharmacodynamic Markers to Facilitate the Discovery of Neurotherapeutics (R21/R33)

This funding opportunity announcement (FOA) encourages the development and validation of: 1) animal models and human tissue ex vivo systems that recapitulate the phenotypic and physiologic characteristics of a defined neurological disorder and/or 2) clinically feasible pharmacodynamic markers for therapeutics designed to treat neurological disease. The goal of this FOA is to promote a significant improvement in the translational relevance of animal models, ex vivo systems, testing paradigms, and endpoints that will be utilized to facilitate the development of neurotherapeutics. Ideally, endpoints proposed in applications for this FOA would have the potential to provide feasible and meaningful assessments of efficacy following therapeutic intervention that would be applicable in both preclinical and clinical settings.

Receipt Dates: June 21, 2016; October 18, 2016; February 21, 2017; June 21, 2017; October 18, 2017

Frequently Asked Questions

IGNITE Q&A Webinar May 11, 2016 (pdf, 594kb)

Milestone Examples

Awarded Grants


 

Grant Program Entry Criteria End Goal Time Budget Limit
PAR-15-070: Assay Development and Therapeutic Agent Identification and Characterization to Support Therapeutic Discovery (R21/R33) Rationally selected assay(s) and therapeutic agents Testing funnel to triage candidates, a battery of assays and starting agents that are well profiled 3 years total for both R21 and R33 stages, with no more than 2 years in either stage. Total direct costs may not exceed $750,000 for the entire 3-year project period, with no more than $250,000 for the R21 phase, and with no more than $500,000 in direct costs in any single year.
PAR-15-071: Pharmacodynamics and In vivo Efficacy Studies for Small Molecules and Biologics/Biotechnology Products (R21/R33) Evidence of validated/characterized animal model and PD measure, testing protocol and therapeutic agents Well-characterized early-stage agents suitable for optimization 3 years total for both R21 and R33 stages, with no more than 2 years in either stage. Total direct costs may not exceed $750,000 for the entire 3-year project period, with no more than $250,000 for the R21 phase, and with no more than $500,000 in direct costs in any single year.
 RFA-NS-16-013: Development and Validation of Model Systems and/or Pharmacodynamic Markers to Facilitate the Discovery of Neurotherapeutics (R21/R33) Translational rationale for the proposed model system or pharmacodynamic marker and evidence of value for future drug discovery/development Translationally relevant animal models, ex vivo systems, testing paradigms, and endpoints 3 years total for both R21 and R33 stages, with no more than 2 years in either stage. Total direct costs may not exceed $250,000 per year, regardless of grant phase

 

Tips and Tools for Applicants


Let Us Know What You Think

Can't find what you're looking for? What else would you like to see? We want your feedback!
Please contact  John Sheridan

Last Modified May 17, 2016